We asked multiple biopharma CEOs everything from which executives or companies they pay close attention to in and outside of their industry, to questions about geopolitical issues, tech trends, and everything in between.
Chief editor, Rob Wright, discusses some forward-looking sessions from the annual CNS Summit, along with what to expect in Life Science Leader’s annual outlook issue.
Industry experts answer questions around future biopharma manufacturing trends, challenges, technologies, performance metrics, risk mitigation, people, and outsourcing.
We connected with a collection of biopharma financial experts to get you prepared for JPM, BTS, and the BIO CEO & Investors Conference in the first quarter of 2019.
Rob Wright shares what makes the CNS Summit the best conference he has ever attended.
A tour of the Netherlands’ life sciences industry takes our chief editor back to the global headquarters of his former employer, Organon Pharmaceuticals.
Liz Barrett recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.
What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.
When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.